NYRNYRADA INC.
Announcement history available from 1 August 2025
Fromto
| Date / Time | Title | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 21 Aug 2026, 18:50 | Xolatryp Demonstrates Cardioprotection in Preclinical Study | Company Update | MS | 11001 | |
| 18 Aug 2026, 23:08 | Nyrada Full Year Results FY2026 | Financial Results | — | 03003 | |
| 18 Aug 2026, 23:08 | Annual Report for year ended 30 June 2026 | Financial Results | — | 03001, 03002, 03011, 03012, 03013, 03020 | |
| 18 Aug 2026, 23:05 | Preliminary Final Report | Financial Results | MS | 03003 | |
| 18 Aug 2026, 23:04 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 5 Aug 2026, 20:01 | Change in substantial holding - M Azzi | Substantial Holders | — | 02006 | |
| 5 Aug 2026, 19:16 | CSANZ26 Conference Poster | Company Update | — | 11001 | |
| 27 July 2026, 18:44 | Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19004, 19009 | |
| 16 July 2026, 02:58 | Response to ASX Price Query | ASX Query | MS | 17003 | |
| 16 July 2026, 02:39 | Change in substantial holding - M Azzi | Substantial Holders | — | 02006 | |
| 6 July 2026, 19:39 | PROTECT-MI Phase IIa Clinical Trial Update No 2 | Company Update | — | 11001 | |
| 1 July 2026, 03:43 | Notification of cessation of securities - NYR | Other | — | 06027 | |
| 30 June 2026, 19:48 | Cleansing Statement | Securities Administration | — | 06018 | |
| 30 June 2026, 19:46 | Application for quotation of securities - NYR | Other | — | 06020 | |
| 30 June 2026, 04:11 | Cleansing Statement | Securities Administration | — | 06018 | |
| 30 June 2026, 04:10 | Application for quotation of securities - NYR | Other | — | 06020 | |
| 17 June 2026, 02:42 | Cleansing Statement | Securities Administration | — | 06018 | |
| 17 June 2026, 02:39 | Application for quotation of securities - NYR | Other | — | 06020 | |
| 16 June 2026, 18:25 | Change of Director's Interest Notice - JB | Director Interests | — | 02009 | |
| 16 June 2026, 18:24 | PROTECT-MI Phase IIa Clinical Trial Update | Company Update | — | 11001 | |
| 4 June 2026, 19:39 | Investor Presentation | Presentations | — | 03026 | |
| 3 June 2026, 23:39 | Nyrada Successfully Completes Cardioprotection Pilot Study | Company Update | — | 11001 | |
| 29 May 2026, 19:45 | Nyrada Receives A$2.455M R&D Tax Incentive Rebate | Periodic Reports | — | 03014 | |
| 26 May 2026, 03:19 | Cleansing Statement | Securities Administration | — | 06018 | |
| 26 May 2026, 03:15 | Application for quotation of securities - NYR | Other | — | 06020 | |
| 21 May 2026, 22:56 | Upcoming Expiry of Unlisted Options | Letters & Addresses | — | 06009, 16001 | |
| 20 May 2026, 19:13 | Xolatryp Enhances Anthracycline Anti-Tumour Efficacy | Company Update | MS | 09014, 11001 | |
| 20 May 2026, 02:54 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 20 May 2026, 01:37 | Pause in Trading | Trading Halt / Suspension | MS | 09005 | |
| 20 May 2026, 01:10 | Nyrada Receives Notice of Allowance for Xolatryp US Patent | Company Update | MS | 11001 | |
| 22 Apr 2026, 22:30 | First Site Activated in Nyradas PROTECT-MI Phase IIa Trial | Company Update | — | 11001 | |
| 15 Apr 2026, 18:45 | Quarterly Activities Report and Appendix 4C | Quarterly Reports | MS | 19003, 19008 | |
| 20 Mar 2026, 19:37 | Presentation - ASX SMIDCaps Conference | Presentations | — | 03026 | |
| 19 Mar 2026, 20:55 | Nyrada PROTECT-MI Phase IIa Trial To Commence | Company Update | — | 11001 | |
| 10 Mar 2026, 04:17 | Change of Director's Interest Notice - JM | Director Interests | — | 02009 | |
| 21 Feb 2026, 04:10 | Director Options Issue | Securities Administration | — | 06009 | |
| 21 Feb 2026, 04:06 | Change of Director's Interest Notice - RW | Director Interests | — | 02009 | |
| 21 Feb 2026, 04:06 | Change of Director's Interest Notice - MF | Director Interests | — | 02009 | |
| 21 Feb 2026, 04:06 | Change of Director's Interest Notice - JM | Director Interests | — | 02009 | |
| 21 Feb 2026, 04:05 | Change of Director's Interest Notice - ID | Director Interests | — | 02009 | |
| 21 Feb 2026, 04:05 | Change of Director's Interest Notice - CC | Director Interests | — | 02009 | |
| 21 Feb 2026, 03:49 | Notification regarding unquoted securities - NYR | Other | — | 06021 | |
| 19 Feb 2026, 01:08 | Capital Structure Update | Securities Administration | — | 06009 | |
| 19 Feb 2026, 01:05 | Top 20 CDI Holder List | Securities Administration | — | 03002 | |
| 19 Feb 2026, 01:02 | Nyrada Half Year FY2026 Results | Financial Results | — | 03004, 03014 | |
| 19 Feb 2026, 00:58 | Appendix 4D and Half Year Report to 31 December 2025 | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 6 Feb 2026, 04:17 | Cleansing Statement | Securities Administration | — | 06018 | |
| 6 Feb 2026, 04:15 | Application for quotation of securities - NYR | Other | — | 06020 | |
| 5 Feb 2026, 19:21 | Investor Update Webinar | Presentations | — | 03026 | |
| 5 Feb 2026, 19:21 | Nyrada Phase IIa Clinical Trial Factsheet | Company Update | — | 11001 |
1–50 of 135
1 / 3